Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA, significantly widening the eligible treatment population in the U.S. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer patch in the share price, with a 30 day share price return of a 3.68% decline and a 1 year total shareholder return of a 7.96% decline. However, the 3 year and 5 year total shareholder returns of 36.02% and 104.45% indicate that the longer term trend has still rewarded patient holders. If this kind of healthcare breakthrough has your attention, it could be a good moment to scan for other potential winners using our screener of 34 healthcare AI stocks With Vertex shares around US$443.92, a 41% intrinsic discount estimate and a 23% gap to the average analyst target, the key question is simple: is this a genuine mispricing or is the market already baking in fut
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals (VRTX) was given a new $612.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
- Vertex to Announce First Quarter 2026 Financial Results on May 4thBusiness Wire
- Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand [Seeking Alpha]Seeking Alpha
- Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 4/3/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- VRTX's page on the SEC website